U.S. Food and Drug Administration Accepts for Priority Review the Biologics License Application for Empliciti (elotuzumab) for the Treatment of Multiple Myeloma in Patients Who Have Received One or More Prior Therapies
September 01, 2015 at 07:30 AM EDT
Bristol-Myers Squibb Company (NYSE: BMY) and AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) has ...